Business Context and Reporting Period
Company: CryoLife, Inc. (Note: Metadata listed "Artivion, Inc." but filing text confirms registrant is CryoLife, Inc.)
Filing Type: Form 10-Q (Unaudited)
Period Ended: March 31, 2001
Business Overview: CryoLife provides human vascular and connective tissue cryopreservation services, bioprosthetic cardiovascular devices, and surgical adhesives (BioGlue). The company is expanding its corporate headquarters and manufacturing facilities.
Key Financial Metrics
| Metric (in thousands) | Q1 2001 | Q1 2000 |
|---|---|---|
| Total Revenues | $21,432 | $19,623 |
| Net Income | $2,478 | $1,604 |
| Earnings Per Share (Diluted) | $0.13 | $0.09 |
| Operating Cash Flow | $1,341 | $1,440 |
| Cash & Cash Equivalents | $15,668 | $5,915 |
| Marketable Securities | $20,209 | $21,234 |
| Total Debt (Current + Long-term) | $12,033 | $12,033 |
| Net Working Capital | $67,241 | $68,449 |
Note: Debt figures include bank loans ($6.15M), convertible debentures ($4.39M), and capital lease obligations ($1.49M). Interest income net of expense was $562,000 for Q1 2001.
Material Changes vs. Prior Period
- Revenue Growth: Total revenues increased 9% to $21.4 million, driven by a 116% surge in BioGlue surgical adhesive sales ($2.4M) and a 34% increase in knee connective tissue services ($5.2M).
- Profitability: Net income rose 54% to $2.5 million. Gross margins improved as the cost of preservation services decreased as a percentage of revenue (43% in 2001 vs. 47% in 2000), aided by higher-margin BioGlue sales.
- Expense Trends: General, administrative, and marketing expenses increased 16% to $8.2 million, largely due to the inclusion of three full months of operations for CryoLife Europa, Ltd. Research and development expenses decreased 18% to $1.1 million due to the timing of pre-clinical studies.
- Portfolio Shift: Revenues from the "Ideas For Medicine" (IFM) segment dropped to zero following the sale of IFM assets in October 2000. Heart valve revenues decreased 9% due to lower procurement volumes.
Guidance, Outlook, and Risks
- Liquidity: Management anticipates current cash, marketable securities, and an $8 million drawn line of credit (part of a $10M facility) will meet needs for the next 12 months. The line of credit converts to a term loan on June 1, 2001.
- Strategic Initiatives: The company is seeking a private placement of equity for its Activation Control Technology (ACT) via a subsidiary, AuraZyme Pharmaceutical, Inc., to fund commercial development without direct R&D expenditure. Development of light activation technology has ceased pending a partner.
- Seasonality: Demand for heart valve services is seasonal, peaking in Q2 and Q3. Other product lines do not exhibit significant seasonality.
- Risks: Key risks include the inability to secure an investor for ACT technology, delays in FDA approvals for clinical trials, changes in government regulation, and the availability of tissue for implant. Interest rate risk exists as $8 million of debt is variable rate, though a $4 million swap agreement is designated to hedge this exposure starting June 2001.
Investor Verification Checklist
- ACT Technology Funding: Verify the status of the private placement for AuraZyme Pharmaceutical, Inc. and the timeline for securing a corporate partner.
- Debt Conversion: Confirm the terms and interest rate implications of the line of credit converting to a term loan on June 1, 2001.
- BioGlue Sustainability: Assess whether the 116% revenue growth in BioGlue is sustainable or driven by one-time market acceptance factors.
- Capital Expenditures: Monitor cash burn related to the expansion of corporate headquarters and manufacturing facilities, which drove investing cash outflows to $3.4 million in Q1.
- IFM Note Receivable: Verify the collection status of the remaining note receivable from LeMaitre Vascular, Inc. following the asset sale.